The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

The Determine Antenatal Care Panel is used for the simultaneous detection of infectious diseases that threaten maternal and pediatric health.

FulgentExome, which covers more than 4,600 genes validated for diagnostic use, is now authorized under Europe's In Vitro Diagnostic Regulation.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate ...